Artificial intelligence is no longer a future-facing innovation in biotech. In 2026, it is a strategic differentiator and increasingly, a board-level expectation.
From AI-driven target discovery and predictive toxicology to intelligent clinical trial modeling and automated regulatory analysis, artificial intelligence is accelerating how biotech companies operate. But the most profound transformation is not technological.
It is leadership-driven.
Biotech boards are redefining what they expect from senior leaders. CEOs, CSOs, CMOs, and COOs are no longer evaluated solely on scientific acumen, regulatory fluency, and capital stewardship. They are now assessed on their ability to understand, integrate, govern, and strategically deploy AI across the organization.